3,3′-Diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through MicroRNA signaling pathways

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 2, 2014, Pages 341-352

  Rouse, Michael ^a   Rao, Roshni ^a   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; B CELL LYMPHOMA 2 PROTEIN; CD28 ANTIGEN; CD69 ANTIGEN; CONCANAVALIN A; CYCLIN D1; CYCLIN E1; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; MICRORNA; MICRORNA 146A; MICRORNA 16; MICRORNA 200C; MICRORNA 22; MICRORNA 93; PROTEIN BCL 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; 3,3'-DIINDOLYLMETHANE; INDOLE DERIVATIVE; RUNX1 PROTEIN, MOUSE;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BCL2 GENE; BIOINFORMATICS; CCND1 GENE; CCNE1 GENE; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL INFILTRATION; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; ERBB3 ENE; ERBB4 GENE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HISTOPATHOLOGY; INCIDENCE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; RUNX1 GENE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL CYCLE CHECKPOINT; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 2 SUBUNIT; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INDOLES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICRORNAS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84904966130     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214742     Document Type: Article

References (54)

1. Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, Farmer PB, Steward WP, and Williams ML (2004) Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res 10:5233-5241.
2. Asou N (2003) The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol 45:129-150.
3. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, and Bartel DP (2008) The impact of microRNAs on protein output. Nature 455:64-71.
4. Bates D (2009) Alemtuzumab. Int MS J 16:75-76.
5. Bernardin-Fried F, Kummalue T, Leijen S, Collector MI, Ravid K, and Friedman AD (2004) AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem 279:15678-15687.
6. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, and Martin R (2009) Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66:483-489.
7. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, and Xu J, et al (2011) miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 208:1189-1201.
8. Busbee PB, Rouse M, Nagarkatti M, and Nagarkatti PS (2013) Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutr Rev 71:353-369.
9. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
10. Chiba K and Adachi K (2012) Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis. Future Med Chem 4:771-781.
11. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, and Dono M, et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944-13949.
12. Cock IE and van Vuuren SF (2014) Anti-Proteus activity of some South African medicinal plants: their potential for the prevention of rheumatoid arthritis. Inflammopharmacology 22:23-36.
13. Coles AJ (2013) Alemtuzumab treatment of multiple sclerosis. Semin Neurol 33:66-73.
14. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman LE, and O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group (2012) Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 18:1278-1289.
15. Dijkstra CD, De Groot CJA, and Huitinga I (1992) The role of macrophages in de-myelination. J Neuroimmunol 40:183-188.
16. Dong L, Xia S, Gao F, Zhang D, Chen J, and Zhang J (2010) 3,3'-Diindolylmethane attenuates experimental arthritis and osteoclastogenesis. Biochem Pharmacol 79: 715-721.
17. Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, and Pei G (2009) MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 10:1252-1259.
18. Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, Liuzzi F, Croce CM, Brunetti E, Grignani F, and Peschle C (2007) MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 9:775-787.
19. Fox EJ (2006) Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther 28:461-474.
20. Gattenloehner S, Chuvpilo S, Langebrake C, Reinhardt D, Müller-Hermelink HK, Serfling E, Vincent A, and Marx A (2007) Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood 110: 2027-2033.
21. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, and Musch B, et al.; CLARITY Study Group (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416-426.
22. Grotenhermen F and Müller-Vahl K (2012) The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 109:495-501.
23. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, and Panitch H, et al.; OLYMPUS trial group (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460-471.
24. He L and Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522-531.
25. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kuwabara Y, Nakashima Y, Takanabe-Mori R, and Nishi E, et al. (2010) Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87:656-664.
26. Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, Lassmann H, Wekerle H, Hohlfeld R, and Meinl E (2009) MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132: 3342-3352.
27. Kim EJ, Park H, Kim J, and Park JH (2010) 3,3'-diindolylmethane suppresses 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediators. Mol Carcinog 49:672-683.
28. Kraus MH, Issing W, Miki T, Popescu NC, and Aaronson SA (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86:9193-9197.
29. Kumar P, Luo Y, Tudela C, Alexander JM, and Mendelson CR (2013) The c-Mycregulated microRNA-17-92 (miR-17-92) and miR-106a-363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol Cell Biol 33:1782-1796.
30. Lee H and Maihle NJ (1998) Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues. Oncogene 16:3243-3252.
31. Lerner A, Grafi-Cohen M, Napso T, Azzam N, and Fares F (2012) The indolic diet-derivative, 3,3'-diindolylmethane, induced apoptosis in human colon cancer cells through upregulation of NDRG1. J Biomed Biotechnol 2012:256178.
32. Li XJ, Park ES, Park MH, and Kim SM (2013) 3,3'-Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway. Oncol Rep 30:2419-2426.
33. Ling B, Wang GX, Long G, Qiu JH, and Hu ZL (2012) Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol 138:1355-1361.
34. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z, and Zheng X (2008) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36:5391-5404.
35. Lodish HF, Zhou B, Liu G, and Chen CZ (2008) Micromanagement of the immune system by microRNAs. Nat Rev Immunol 8:120-130.
36. Lorenzi JC, Brum DG, Zanette DL, de Paula Alves Souza A, Barbuzano FG, Dos Santos AC, Barreira AA, and da Silva WA (2012) miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients. Int J Neurosci 122:466-471.
37. Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N, and Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77-92.
38. Nachshon-Kedmi M, Yannai S, Haj A, and Fares FA (2003) Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 41:745-752.
39. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, and Wu JC (2013) Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther 38:854-863.
40. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, and Baltimore D (2010a) MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33:607-619.
41. O'Connell RM, Rao DS, Chaudhuri AA, and Baltimore D (2010b) Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10:111-122.
42. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, and Gallo P (2012) Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Mult Scler 18:1760-1767.
43. Rouse M, Singh NP, Nagarkatti PS, and Nagarkatti M (2013) Indoles mitigate the development of experimental autoimmune encephalomyelitis by induction of reciprocal differentiation of regulatory T cells and Th17 cells. Br J Pharmacol 169: 1305-1321.
44. Schreiner B, Heppner FL, and Becher B (2009) Modeling multiple sclerosis in laboratory animals. Semin Immunopathol 31:479-495.
45. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, and Rajewsky N (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455:58-63.
46. Sethi A, Kulkarni N, Sonar S, and Lal G (2013) Role of miRNAs in CD4 T cell plasticity during inflammation and tolerance. Front Genet 4:8.
47. Siffrin V, Brandt AU, Herz J, and Zipp F (2007) New insights into adaptive immunity in chronic neuroinflammation. Adv Immunol 96:1-40.
48. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, and Nagarkatti P (2007) Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72:1508-1521.
49. Stresser DM, Williams DE, Griffin DA, and Bailey GS (1995) Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Drug Metab Dispos 23:965-975.
50. Tian L, De Hertogh G, Fedeli M, Staats KA, Schonefeldt S, Humblet-Baron S, Van Den Bosch L, Dellabona P, Dooley J, and Liston A (2012) Loss of T cell microRNA provides systemic protection against autoimmune pathology in mice. J Autoimmun 38:39-48.
51. Walther EU and Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53:1622-1627.
52. Xiao BG, Diab A, Zhu J, van der Meide P, and Link H (1998) Astrocytes induce hyporesponses of myelin basic protein-reactive T and B cell function. J Neuroimmunol 89:113-121.
53. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, and Hyslop T, et al. (2008) A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182:509-517.
54. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, and Liu P (2012) miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69:723-731.